+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Autoradiographic Localization of Peripheral Benzodiazepine, Dihydroalprenolol and Arginine Vasopressin Binding Sites in the Pituitaries of Control, Stalk Transected and Brattleboro Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          T he autoradiographic distribution of [<sup>3</sup>H]arginine vasopressin, [<sup>3</sup>H]spiperone, [<sup>3</sup>H]GABA, [<sup>3</sup>H]dihydroalprenolol and the peripheral-type benzodiazepine ligand [<sup>3</sup>H]Ro5-4864 were examined in the rat pituitary before and after pituitary stalk transection. Stalk transection produced dramatic changes in the cellular architecture of the pars nervosa. Glial fibrillary acidic protein, an astrocyte marker reported in pituicytes, increased after stalk transection, whereas neurofilament, a marker for neuronal innervation, was lost. These structural changes demonstrated a successful stalk transection, permitting interpretation of changes in the densities of several [<sup>3</sup>H]-ligands over the three lobes. [<sup>3</sup>H]Ro5-4864 binding was markedly increased, suggesting that this site was located on the pituicytes. Conversely [<sup>3</sup>H]spiperone and [<sup>3</sup>H]arginine vasopressin binding density over the pars nervosa decreased. In the mutant diabetes insipidus rat (Brattleboro), which lacks pituitary vasopressin, [<sup>3</sup>H]arginine vasopressin binding was undetectable in the pars nervosa. [<sup>3</sup>H]dihydroalprenolol and [<sup>3</sup>H]GABA binding sites were unchanged by the lesion. These results are discussed in terms of the occurrence of functional acceptors on pituicytes and their possible role in neurohydrophyseal secretions.

          Related collections

          Author and article information

          S. Karger AG
          01 April 2008
          : 44
          : 1
          : 76-83
          Department of Biochemistry, Imperial College of Science and Technology, London, UK
          124625 Neuroendocrinology 1986;44:76–83
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article